Dialysis Drug Reimbursement Should Be Based Solely On ASP, MedPAC Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare Payment Advisory Committee unanimously recommends average sales price-based reimbursement for dialysis drugs in all settings. More timely updating of payment rates is cited as the main advantage of ASP-based reimbursement over reimbursement based on average acquisition payment.